The AIM-HI Accelerator Fund is proud to announce the seven semi-finalists of the 2026 AIM-HI Venture Competition. Each year, the Venture Competition connects the most promising early-stage oncology founders with the funding opportunities, expert guidance, and a global network of oncology innovation leaders — accelerating the path from breakthrough science to treatments that reach patients.
🚀 Meet the 2026 Semi-Finalists (in alphabetical order):
- Cellinfinity Bio
- Nemea Therapeutics
- RedPoint Oncology
- Resolute Science
- Talus Bio
- Trojan Bio
- VerImmune
Selected from a highly competitive global applicant pool, the seven semi-finalists represent the most promising early-stage oncology companies working to address cancer’s most urgent challenges.
In the next phase of the competition, the semi-finalists will present their visions to a world-class Judging Committee of visionary leaders in oncology, whose expertise will help identify the companies with the greatest potential to advance the future of cancer innovation.
The top finalists will then advance to a rigorous due diligence process led by the Investment Committee. Each company will be evaluated on the strength of its science, the significance of the unmet patient need it addresses, and its potential to generate both patient impact and sustainable investment returns. Those who passes the due diligence process will be recognized at the 2026 NFCR Global Summit and Award Ceremonies for Cancer Research and Entrepreneurship, co-hosted by AIM-HI, on October 9, 2026, at the National Press Club in Washington, DC and will become eligible for seed investment from AIM-HI and its co-investors.
